Galectin Therapeutics (GALT) Return on Capital Employed (2011 - 2026)
Galectin Therapeutics (GALT) posted quarterly Return on Capital Employed of 157.32% for Q1 2026, down 19912.0% year-over-year from N/an in Q1 2025, and up 36.02% quarter-over-quarter from 245.88% in Q4 2025.
Galectin Therapeutics (GALT) Return on Capital Employed (2011 - 2026) Analysis & Trends
Galectin Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 157.32% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 19912.0% year-over-year to 157.32%; the TTM figure through Mar 2026 stood at 157.32% (down 19912.0% YoY), while the FY2025 annual figure was 191.59%, down 52939.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 157.32%, up from 245.88% in the prior quarter.
- The five-year high for Return on Capital Employed was 348.51% in Q4 2024, with the low at 1899.27% in Q2 2025.
- The 5-year median for Return on Capital Employed is 285.45% (2022), against an average of 382.77%.
- Peak annual rise in Return on Capital Employed reached 131876 bps in 2025, while the deepest fall reached 157295 bps in 2025.
- Galectin Therapeutics' Return on Capital Employed stood at 582.19% in 2022, then soared by 31 bps to 400.53% in 2023, then soared by 187 bps to 348.51% in 2024, then slumped by 171 bps to 245.88% in 2025, then soared by 36 bps to 157.32% in 2026.
- Business Quant data shows GALT's Return on Capital Employed at 157.32% in Q1 2026, 245.88% in Q4 2025, and 23.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | -157.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.32% |
| Dec 31, 2025 | -245.88% |
| Sep 30, 2025 | 23.85% |
| Jun 30, 2025 | -1,899.27% |
| Mar 31, 2025 | 41.80% |
| Dec 31, 2024 | 348.51% |
| Sep 30, 2024 | -1,294.91% |
| Jun 30, 2024 | -326.32% |
| Mar 31, 2024 | -259.35% |
| Dec 31, 2023 | -400.53% |
| Sep 30, 2023 | -369.28% |
| Jun 30, 2023 | -373.53% |
| Mar 31, 2023 | -420.29% |
| Dec 31, 2022 | -582.19% |
| Sep 30, 2022 | -285.45% |
| Jun 30, 2022 | -187.00% |
| Mar 31, 2022 | -119.91% |
| Dec 31, 2021 | -97.67% |
| Sep 30, 2021 | -111.54% |
| Jun 30, 2021 | -127.93% |